## DVA: DaVita Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.5% below STRENGTH zone (3.0-6.0%); PEG 1.09 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($109.97)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 8
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Who Owns DaVita? Top Shareholders and Recent Insider Trades**
- Source: TIKR.com | 20260102T120747 | Neutral | Relevance: 100%
- DaVita Inc. (NYSE: DVA) is primarily owned by Berkshire Hathaway Inc., which holds a significant 44.98% stake, despite a recent reduction. Other major shareholders include institutional investors like The Vanguard Group and BlackRock, with some hedge funds increasing their positions following a stock pullback. Insider trading shows a mix of selling activity from officers and directors, alongside equity-related entries, suggesting a cautious approach to managing personal exposure rather than strong conviction at current prices.

**2. DaVita stock under the microscope: cautious optimism meets reimbursement risk**
- Source: AD HOC NEWS | 20260102T082307 | Neutral | Relevance: 100%
- DaVita's stock has seen a multi-month uptrend, driven by upbeat Street targets, but faces constant threats from U.S. healthcare policy changes, payer mix adjustments, and potential reimbursement decisions. While recent performance shows a double-digit percentage gain over the last year, the company's future hinges on stable reimbursement, sustained operating margins amid wage pressures, and successful expansion into risk-bearing and coordinated kidney care contracts. Wall Street's sentiment is cautiously positive, with most firms rating it a "Hold" or "Buy," citing improved reimbursement visibility and cost controls.

**3. DaVita Inc Is Suddenly On Everyone’s Radar – But Is DVA Stock Actually Worth Your Money?**
- Source: AD HOC NEWS | 20260101T110755 | Somewhat-Bullish | Relevance: 100%
- DaVita Inc. is gaining attention on Wall Street as a potential "sleeper hit" despite operating in the niche dialysis sector. The article examines the hype, risks, and fundamentals of DVA stock, comparing it to its main competitor, Fresenius Medical Care. It concludes that DaVita is not a quick profit stock but could be a valuable long-term healthcare investment for those willing to navigate regulatory and policy challenges.

**4. DaVita Inc Is Suddenly On Everyone’s Radar – But Is DVA Stock Actually Worth Your Money?**
- Source: AD HOC NEWS | 20260101T104113 | Neutral | Relevance: 100%
- DaVita Inc. is gaining attention on Wall Street due to its significant role in chronic healthcare, specifically dialysis. The article explores whether DVA stock is a worthwhile investment, given its stable demand but also its vulnerability to regulatory risks and rising costs. It also compares DaVita Inc. to its main competitor, Fresenius Medical Care, highlighting key differences for long-term investors.

**5. DaVita Inc. $DVA Shares Sold by Voya Investment Management LLC**
- Source: MarketBeat | 20251231T130743 | Somewhat-Bearish | Relevance: 100%
- Voya Investment Management LLC significantly reduced its stake in DaVita Inc. by 63.0% in Q3, selling 14,794 shares. Despite this, other major institutions like Amundi, KBC Group NV, Man Group plc, Nordea Investment Management AB, and Wedge Capital Management L L P NC increased their holdings, with institutional ownership standing at 90.12%. Analysts have mostly given DaVita a "Hold" rating with an average target price of $148.00, following the company missing Q3 EPS estimates and providing FY2025 guidance of $10.35-$11.15 EPS.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($54.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 69.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Berkshire Hathaway, : 45.6% (-4.8%)
- Vanguard Group Inc: 6.0% (-10.9%)
- Blackrock Inc.: 5.1% (-13.1%)
- State Street Corpora: 2.6% (-12.4%)
- Invesco Ltd.: 2.4% (+2.0%)

### Key Risks

1. Heavy insider selling: $55M sold (3 transactions in 90 days).
2. High short interest (21.1%, 7.3 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 14.6% below SMA200.

### Catalysts

- Momentum building: MRS_10 improving +4.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.09 suggests fair value with growth premium. Forward P/E 9.0x attractive for 19% earnings growth. Quality metrics strong (ROE 62%). Insider selling cluster ($55.0M in 90 days), potential headwind. Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $8.2B |
| Beta | 0.99 |
| 52W Range | $112.54 - $179.60 |
| Short Interest | 21.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.09 |
| Forward P/E | 9.0 |
| Current P/E | 10.7 |
| YoY Growth | 19.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.9% to 0.5% (+4.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.5pp (needs >3.0% for momentum thesis). MRS_5 at 1.2% confirms short-term momentum alignment. Below SMA200 (0.85x), long-term trend not supportive. RSI neutral at 40. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.53% (CS: 47) | Neutral |
| RSI_14 | 40.3 | Neutral |
| MACD Histogram | -0.15 | Bearish |
| vs SMA20 | 0.982x | Below |
| vs SMA50 | 0.958x | Below |
| vs SMA200 | 0.854x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $114.51
- **Stop Loss:** $109.97 (4.0% risk)
- **Target:** $119.05 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 317
- **Position Value:** $36,299.67
- **Portfolio %:** 36.30%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-12 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.17 | $2.51 | -20.9% |
| 2025Q2 | $2.75 | $2.95 | +7.3% |
| 2025Q1 | $2.02 | $2.00 | -0.9% |
| 2024Q4 | $2.13 | $2.24 | +5.4% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*